Metozolv ODT changes the way you take metoclopramide

Patient tools and resources

If you're just learning about diabetic gastroparesis or refractory GERD, or about Metozolv ODT (metoclopramide HCl) as a treatment option, this section can be a helpful resource for you. Here, you will find important information, links to other helpful web sites, and tools, such as diabetic gastroparesis and refractory GERD diet tips.

Please remember that these tools are not intended to replace the guidance of your healthcare professional. Please discuss your treatment options with him or her.

Is Metozolv ODT right for you?

  • Discussion guide—Suggested questions to ask your healthcare professional about treatment with Metozolv ODT
  • Patient examples—See examples of how treatment with Metozolv ODT can help

Dietary tools

  • Diabetic gastroparesis and refractory GERD diet tips—Learn how paying attention to what you eat may impact symptoms
  • Understanding food labels—Discover how to make sense of nutrition labels on your favorite foods and drinks
  • BMI calculator—Calculate your body mass index (BMI) to help determine your body fat level, and learn how it relates to diabetic gastroparesis and refractory GERD
  • Food diary—Keep track of what and when you eat to record food- and time-related symptoms and to help maintain a healthy weight
Online resources Glossary of terms Play the Tip of the Tongue Trivia Challenge Pass on the word about Metozolv ODT

IMPORTANT SAFETY INFORMATION

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms; neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience withdrawal symptoms after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Please see accompanying full Prescribing Information for Metozolv ODT, including BOXED WARNING.

Sign up to receive updates about Metozolv ODT Questions to ask your healthcare professional Play the Tip of the Tongue Trivia Challenge
footer image